EP1578915A4 - Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof - Google Patents

Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof

Info

Publication number
EP1578915A4
EP1578915A4 EP02802862A EP02802862A EP1578915A4 EP 1578915 A4 EP1578915 A4 EP 1578915A4 EP 02802862 A EP02802862 A EP 02802862A EP 02802862 A EP02802862 A EP 02802862A EP 1578915 A4 EP1578915 A4 EP 1578915A4
Authority
EP
European Patent Office
Prior art keywords
astrocytes
neurons
methods
tumor cells
inhibiting proliferation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP02802862A
Other languages
German (de)
French (fr)
Other versions
EP1578915A2 (en
Inventor
David E Weinstein
Carlos Suarez
Marielba Zerlin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Albert Einstein College of Medicine
Original Assignee
Albert Einstein College of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Albert Einstein College of Medicine filed Critical Albert Einstein College of Medicine
Publication of EP1578915A2 publication Critical patent/EP1578915A2/en
Publication of EP1578915A4 publication Critical patent/EP1578915A4/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Virology (AREA)
  • General Physics & Mathematics (AREA)
  • Toxicology (AREA)
EP02802862A 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof Ceased EP1578915A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US34471201P 2001-11-07 2001-11-07
US344712P 2001-11-07
PCT/US2002/035588 WO2003040333A2 (en) 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof

Publications (2)

Publication Number Publication Date
EP1578915A2 EP1578915A2 (en) 2005-09-28
EP1578915A4 true EP1578915A4 (en) 2008-02-13

Family

ID=23351677

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02802862A Ceased EP1578915A4 (en) 2001-11-07 2002-11-07 Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof

Country Status (6)

Country Link
EP (1) EP1578915A4 (en)
JP (1) JP4503287B2 (en)
AU (1) AU2002363524B2 (en)
CA (1) CA2466334A1 (en)
NZ (1) NZ532989A (en)
WO (1) WO2003040333A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004087882A2 (en) * 2003-03-26 2004-10-14 Washington University Neuregulin protein regulation of synaptic proteins
EP1570857A1 (en) * 2004-02-27 2005-09-07 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO Method for inhibiting the transendothelal migration of cells such as leukocytes or tumor cells by a CD81 binding agent and uses thereof
JP6861349B2 (en) * 2015-09-15 2021-04-21 中西　徹 CD81 LEL-specific monoclonal antibody

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KELIC S ET AL: "CD81 REGULATES NEURON-INDUCED ASTROCYTE CELL-CYCLE EXIT", MOLECULAR AND CELLULAR NEUROSCIENCES, SAN DIEGO, US, vol. 17, 2001, pages 551 - 560, XP002951199, ISSN: 1044-7431 *
MAECKER H T ET AL: "DIFFERENTIAL EXPRESSION OF MURINE CD81 HIGHLIGHTED BY NEW ANTI-MOUSE CD81 MONOCLONAL ANTIBODIES", HYBRIDOMA, LIEBERT, NEW YORK, NY, US, vol. 19, no. 1, February 2000 (2000-02-01), pages 15 - 22, XP009005201, ISSN: 0272-457X *
WEINSTEIN D E ET AL: "C17, a retrovirally immortalized neuronal cell line, inhibits the proliferation of astrocytes and astrocytoma cells by a contact-mediated mechanism.", GLIA 1990, vol. 3, no. 2, 1990, pages 130 - 139, XP002456347, ISSN: 0894-1491 *

Also Published As

Publication number Publication date
JP2005537779A (en) 2005-12-15
WO2003040333A3 (en) 2006-04-27
EP1578915A2 (en) 2005-09-28
CA2466334A1 (en) 2003-05-15
AU2002363524B2 (en) 2008-12-04
JP4503287B2 (en) 2010-07-14
NZ532989A (en) 2009-04-30
WO2003040333A2 (en) 2003-05-15

Similar Documents

Publication Publication Date Title
EP1565187A4 (en) Methods of treating cancer and related methods
HK1162948A1 (en) Hemiasterlin derivatives and uses thereof in the treatment of cancer (hemiasterlin)
AU2003200722A1 (en) Compositions and methods for the treatment of tumor
AU2003200740A1 (en) Compositions and methods for the treatment of tumor
AU2003215460A8 (en) Cancer associated protein kinases and their uses
HK1080840A1 (en) Arylcarbonylpiperazines and heteroarylcarbonylpiperazines and the use thereof for treating benign and malignant tumour diseases
EP1560593A4 (en) Novel composition and methods for the treatment of immune related diseases
KR100510795B1 (en) Compositions and Methods for the Treatment of Tumor
AU2001251613A1 (en) Novel genes, compositions and methods for the identification, assessment, prevention, and therapy of human cancers
AU2003249645A8 (en) Methods for the identification of ikkalpha function and other genes useful for treatment of inflammatory diseases
EP1539197A4 (en) Treatment of tumor cells for use in immunotherapy of cancer
WO2004104039A8 (en) Tumor antigens for prevention and/or treatment of cancer
AU2003272728A8 (en) Methods and compositions for treatment of neurological disorder
AU2003247784A8 (en) Compositions and methods for treatment and detection of multiple cancers
IL156778A0 (en) Methods to identify compounds useful for the treatment of proliferative and differentiative disorders
PL368035A1 (en) Compositions and methods for the treatment of cancer
EP1575497A4 (en) Novel composition and methods for the treatment of psoriasis
EP1578915A4 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and for enhancing survival of neurons and uses thereof
AU2003228339A1 (en) Prevention and treatment of disease using angiogenesis-and/or tumor antigens
IL155791A0 (en) Methods for inhibiting proliferation of astrocytes and astrocytic tumor cells and uses thereof
AU2003219664A1 (en) Methods and therapeutic compositions in the treatment of advanced cancer
HUP0500617A3 (en) Methods for the identification of polypeptide antigens associated with disorders involving aberrant cell proliferation and compositions useful for the treatment of such disorders
EP1576113A4 (en) Tumor antigens bfa4 and bcy1 for prevention and/or treatment of cancer
AU2003231912A1 (en) Methods of detecting and treating prostate cancer
AU2003262847A1 (en) Use of mullerian inhibiting substance and interferon for treating tumors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

PUAK Availability of information related to the publication of the international search report

Free format text: ORIGINAL CODE: 0009015

RIC1 Information provided on ipc code assigned before grant

Ipc: C07H 21/04 20060101ALI20060816BHEP

Ipc: A61K 39/00 20060101ALI20060816BHEP

Ipc: A61K 38/02 20060101ALI20060816BHEP

Ipc: A61K 31/7088 20060101AFI20060816BHEP

17P Request for examination filed

Effective date: 20061012

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

A4 Supplementary search report drawn up and despatched

Effective date: 20080116

17Q First examination report despatched

Effective date: 20081002

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20120420